Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADX10059 in GERD Partial Responders to PPIs
NCT00810485Phase 2Completed
- Sponsor
- Addex Therapeutics Ltd
- Start
- Dec 2008
- Primary completion
- Dec 2009
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, randomised, double-blind trial of raseglurant in gastroesophageal reflux disease (GERD) (4 arms), sponsored by Addex Therapeutics Ltd. Primary endpoint: Number of GERD symptom free days in week 4 of study medication treatment. Started Dec 2008; status: completed.
02
Drugs
raseglurant
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00810485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00810485.